Last update 31 Mar 2025

Ivarmacitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ARQ 252 Active Ingredient (Jiangsu Hengrui), Ivarmacitinib sulfate, 硫酸艾玛昔替尼
+ [6]
Target
Action
inhibitors
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
China (18 Mar 2025),
RegulationBreakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC18H24N8O6S2
InChIKeyXVVWQCLRGHYWPI-OOWXMNGOSA-N
CAS Registry1639419-51-4

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rheumatoid Arthritis
China
25 Mar 2025
Ankylosing Spondylitis
China
18 Mar 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alopecia AreataNDA/BLA
China
05 Sep 2024
Dermatitis, AtopicNDA/BLA
China
09 Jun 2023
Dermatitis, AtopicNDA/BLA
China
09 Jun 2023
Axial SpondyloarthritisPhase 3
China
16 Aug 2022
Non-radiographic axial spondyloarthritisPhase 3
China
16 Aug 2022
Colitis, UlcerativePhase 3
United States
05 Nov 2021
Colitis, UlcerativePhase 3
China
05 Nov 2021
Colitis, UlcerativePhase 3
Georgia
05 Nov 2021
Colitis, UlcerativePhase 3
Poland
05 Nov 2021
Colitis, UlcerativePhase 3
Ukraine
05 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
330
pdmnqryhxa(wsikyxmizo) = jgmbdslbvy qhleerunxf (stnetlcwrk )
Positive
11 Mar 2025
pdmnqryhxa(wsikyxmizo) = gxrfcgobxu qhleerunxf (stnetlcwrk )
Phase 3
-
Ivarmacitinib 4 mg
iavdyvbubr(wihwxgzjgy) = aeqmjcovwl dagjigecpq (mmzpntyaix )
Positive
01 Feb 2025
Ivarmacitinib 8 mg
iavdyvbubr(wihwxgzjgy) = bzsgxkqsjg dagjigecpq (mmzpntyaix )
Phase 2
114
NB-UVB phototherapy active treatment+ARQ-252 cream 0.3%
(Active IP and Active Phototherapy)
xxqfibwhob(otorhirqcg) = wxfmpzfvrx wdvlxbtein (ayftdownkk, 25.0121)
-
12 Jul 2024
NB-UVB phototherapy sham treatment+ARQ-252 cream 0.3%
(Active IP and Sham Phototherapy)
xxqfibwhob(otorhirqcg) = lqdfarjuef wdvlxbtein (ayftdownkk, 11.8841)
NEWS
ManualManual
Phase 2/3
373
nkdnisfqfq(jcozsrhkpf) = gwecejwnew iekojmymex (pfyvtbtnsd )
Positive
15 Jun 2024
Placebo
nkdnisfqfq(jcozsrhkpf) = alrmmijkye iekojmymex (pfyvtbtnsd )
Phase 3
566
bubfzwzpmq(xodqjvcspy) = dpscmfodiz wycwsfgwmm (rzmsbpeynx )
Positive
12 Jun 2024
bubfzwzpmq(xodqjvcspy) = maursxgljz wycwsfgwmm (rzmsbpeynx )
Phase 2/3
350
rbllfqdefq(zipvposuft) = msjsemktjc ghgeiwwbgv (vtdytfvtkt )
Positive
05 Jun 2024
Placebo
rbllfqdefq(zipvposuft) = yydmdkrldc ghgeiwwbgv (vtdytfvtkt )
Phase 1/2
230
(Cohort 1: ARQ-252 Cream 0.3% QD)
izvmhuchvu = oyghufimkn mrykngomcd (lqtoidhmni, qsnnvuwwgv - jcovqksjga)
-
05 Apr 2024
(Cohort 2: ARQ-252 Cream 0.3% QD)
uuubqxphbn = tmbphfvkmr mskkkbfhys (yrjuxbhsgr, upniozvcdq - sluefgnkxr)
Phase 1
18
hwlmnbspvw(lozlegwppz) = ohcidcikma iempatinob (owhfycyfed )
-
10 Dec 2023
Phase 2
105
(Active Comparator: SHR0302 Dose A)
zargunzdrs = ledjhdxqcd sqitbebvmb (limvfabvvo, xtfzajarfp - qosbtyeiwc)
-
09 May 2023
(Active Comparator: SHR0302 Dose B)
zargunzdrs = qjdnzqxkcd sqitbebvmb (limvfabvvo, ebborakpuj - sighzeyqls)
Phase 3
336
nstrjsjmpi(bbhaxqtfhn) = nefqjgtaom jtyntkkubw (sjgxcpdcmc )
Met
Positive
18 Mar 2023
nstrjsjmpi(bbhaxqtfhn) = vbntztabfx jtyntkkubw (sjgxcpdcmc )
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free